65 related articles for article (PubMed ID: 37844109)
1. Client experiences using a new supervised consumption service in Sudbury, Ontario: A qualitative study.
Ali F; Russell C; Kaura A; Leslie P; Bayoumi AM; Hopkins S; Wells S
PLoS One; 2023; 18(10):e0292862. PubMed ID: 37844109
[TBL] [Abstract][Full Text] [Related]
2. Hoots and harm reduction: a qualitative study identifying gaps in overdose prevention among women who smoke drugs.
Bardwell G; Austin T; Maher L; Boyd J
Harm Reduct J; 2021 Mar; 18(1):29. PubMed ID: 33678163
[TBL] [Abstract][Full Text] [Related]
3. To what extent do supervised drug consumption services incorporate non-injection routes of administration? A systematic scoping review documenting existing facilities.
Speed KA; Gehring ND; Launier K; O'Brien D; Campbell S; Hyshka E
Harm Reduct J; 2020 Oct; 17(1):72. PubMed ID: 33028363
[TBL] [Abstract][Full Text] [Related]
4. Perspectives of Canadian Healthcare and Harm Reduction Workers on Mobile Overdose Response Services: A Qualitative Study.
Sedaghat N; Seo B; Rider N; Rioux W; Ghosh SM
Subst Use Addctn J; 2024 Jul; 45(3):506-514. PubMed ID: 38525593
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration.
Wolfson-Stofko B; Elliott L; Bennett AS; Curtis R; Gwadz M
Int J Drug Policy; 2018 Dec; 62():67-73. PubMed ID: 30359875
[TBL] [Abstract][Full Text] [Related]
6. "Another tool in the toolkit"-Perceptions, suggestions, and concerns of emergency service providers about the implementation of a supervised consumption site.
Perlmutter D; Wettemann C; Fockele CE; Frohe T; Williams W; Holland N; Oliphant-Wells T; Meischke H; van Draanen J
Int J Drug Policy; 2023 May; 115():104005. PubMed ID: 36972652
[TBL] [Abstract][Full Text] [Related]
7. Bridging the Gap in Harm Reduction Using Mobile Overdose Response Services (MORS) in the Context of the COVID-19 Pandemic: A Qualitative Study.
Seo B; Rioux W; Rider N; Teare A; Jones S; Taplay P; Ghosh SM
J Urban Health; 2024 Apr; 101(2):252-261. PubMed ID: 38514599
[TBL] [Abstract][Full Text] [Related]
8. A critical narrative inquiry to understand the impacts of an overdose prevention site on the lives of site users.
Oudshoorn A; Sangster Bouck M; McCann M; Zendo S; Berman H; Banninga J; Le Ber MJ; Zendo Z
Harm Reduct J; 2021 Jan; 18(1):6. PubMed ID: 33407553
[TBL] [Abstract][Full Text] [Related]
9. Feasibility, acceptability, concerns, and challenges of implementing supervised injection services at a specialty HIV hospital in Toronto, Canada: perspectives of people living with HIV.
Rudzinski K; Xavier J; Guta A; Chan Carusone S; King K; Phillips JC; Switzer S; O'Leary B; Baltzer Turje R; Harrison S; de Prinse K; Simons J; Strike C
BMC Public Health; 2021 Jul; 21(1):1482. PubMed ID: 34325681
[TBL] [Abstract][Full Text] [Related]
10. Radical hospitality: Innovative programming to build community and meet the needs of people who use drugs at a government-sanctioned overdose prevention site in San Francisco, California.
Wenger LD; Morris T; Knight KR; Megerian CE; Davidson PJ; Suen LW; Majano V; Lambdin BH; Kral AH
Int J Drug Policy; 2024 Apr; 126():104366. PubMed ID: 38492432
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of healthcare workers on the integration of overdose detection technologies in acute care settings.
Rioux W; Kilby K; Jones S; Joshi P; Vandenberg S; Ghosh SM
Addict Sci Clin Pract; 2024 Jan; 19(1):4. PubMed ID: 38217056
[TBL] [Abstract][Full Text] [Related]
12. Accessibility gaps of physical supervised consumption sites in Canada motivating the use of overdose response technology/phone based virtual overdose response services: a retrospective cohort study.
Mocanu V; Viste D; Rioux W; Ghosh SM
Lancet Reg Health Am; 2024 Jun; 34():100770. PubMed ID: 38798948
[TBL] [Abstract][Full Text] [Related]
13. Advancing patient-centered care for structurally vulnerable drug-using populations: a qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals.
McNeil R; Kerr T; Pauly B; Wood E; Small W
Addiction; 2016 Apr; 111(4):685-94. PubMed ID: 26498577
[TBL] [Abstract][Full Text] [Related]
14. Public support for harm reduction: A population survey of Canadian adults.
Wild TC; Koziel J; Anderson-Baron J; Asbridge M; Belle-Isle L; Dell C; Elliott R; Hathaway A; MacPherson D; McBride K; Pauly B; Strike C; Galovan A; Hyshka E
PLoS One; 2021; 16(5):e0251860. PubMed ID: 34010338
[TBL] [Abstract][Full Text] [Related]
15. Virtual Overdose Response for People Who Use Opioids Alone: Protocol for a Feasibility and Clinical Trial Study.
Bristowe SK; Ghosh SM; Trew M; ; Rittenbach K
JMIR Res Protoc; 2021 May; 10(5):e20183. PubMed ID: 33978598
[TBL] [Abstract][Full Text] [Related]
16. Using digital technology to reduce drug-related harms: a targeted service users' perspective of the Digital Lifelines Scotland programme.
Strachan G; Daneshvar H; Carver H; Greenhalgh J; Matheson C
Harm Reduct J; 2024 Jul; 21(1):128. PubMed ID: 38951880
[TBL] [Abstract][Full Text] [Related]
17. In Support of Overdose Prevention Centers: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education and Research in Substance Use and Addiction).
Dunham K; Hill K; Kazal H; Butner JL; Hull I; Sue K; Li L; Doneski K; Dinges B; Rife-Pennington T; Kung S; Thakarar K
Subst Use Addctn J; 2024 Jul; 45(3):328-336. PubMed ID: 38747578
[TBL] [Abstract][Full Text] [Related]
18. How do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities.
Ezell JM; Pho MT; Simek E; Ajayi BP; Shetty N; Walters SM
Harm Reduct J; 2024 Apr; 21(1):79. PubMed ID: 38589920
[TBL] [Abstract][Full Text] [Related]
19. Support for Safe Consumption Sites Among Peer Recovery Coaches.
Pasman E; Brown S; Agius E; Resko SM
J Behav Health Serv Res; 2024 Apr; 51(2):219-231. PubMed ID: 37430133
[TBL] [Abstract][Full Text] [Related]
20. Community perceptions surrounding Lisbon's first mobile drug consumption room.
Taylor H; Leite Â; Gautier D; Nunes P; Pires J; Curado A
Dialogues Health; 2022 Dec; 1():100031. PubMed ID: 38515893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
